An observational study in Diabetic Nephropathy and Dyslipidemia, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-17.
Sponsored by Assiut University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Diabetic Nephropathies by Assiut University — 16 open to participants now, 16 under way, none of them phase 3. Diabetic Nephropathies · Assiut University.
Among the 25 studies in Diabetic Nephropathies by Assiut University, this one is the 13th largest by planned enrollment of the 21 observational ones that give a count, is one of 5 that started in 2026, is one of 21 observational ones, reaches primary completion later than 12 of the 15 other live ones, and was the 21st registered.
544 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.
Browse Diabetic Nephropathies studies →16 of the 25 studies in Diabetic Nephropathies by Assiut University are open now, in 1 country. Recruiting first, the newest first:
Assiut University
Ages 18+ · Healthy volunteers
Assiut University · Sites in Egypt
Ages 18+
Assiut University
Ages 18+
Assiut University
Ages 18–80
Assiut University
Ages 18+
By country, each count listing its studies:
Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 84 is below the median of 188 across 138 observational studies indexed under Diabetic Nephropathies.
Median enrollment 78 across the 4 interventional studies, 92 across the 21 observational. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Diabetic Nephropathies by Assiut University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06690034Assiut UniversityRelationship of Serum Zinc Level with Severity of Diabetic Nephropathy | 2026-12-01 |
| NCT07773467Assiut UniversitySystemic Immune-Inflammation Index and Platelet Parameters in Diabetic Kidney Disease | 2027-09 |
| NCT07813793Assiut UniversityRole of Triglyceride-Glucose Index and Inflammatory Biomarkers as Prognostic Tools for Progression of Diabetic Nephropathy | 2027-10-01 |
| NCT07476248Assiut UniversityThe Non-high-density Lipoprotein Cholesterol (Non-HDL-C) to High-density Lipoprotein Cholesterol (HDL-C) Ratio (NHHR) and Its Association With Occurrence of Diabetic Nephropathy in Patients With Diabetes Mellitus | 2027-10-01 |
| NCT07919795Assiut UniversityBeta-2-Trace Protein in Diabetic Nephropathy | 2027-11-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 25 studies in Diabetic Nephropathies by Assiut University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study aims to examine the relationship between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and CKD in patients with DM.
The study will include adult participants recruited from outpatient clinics and inpatient departments. Participants will be classified into the following groups:
Diabetes Mellitus without Diabetic Nephropathy (DM group) :
Patients with diabetes mellitus who have no evidence of diabetic nephropathy will be defined by a normal urinary albumin-to-creatinine ratio (UACR) and preserved renal function.
Patients with diabetes mellitus and diabetic nephropathy will be defined by the presence of elevated UACR and/or impaired renal function as assessed by estimated glomerular filtration rate (eGFR).
Subgroup Analysis :
Within the diabetic nephropathy group, further subgroup analyses will be performed to assess differences in NHHR according to:
Type of diabetes (Type 1 vs. Type 2 diabetes mellitus) Stages of chronic kidney disease (CKD) are classified based on KDIGO definitions of CKD based on estimated GFR and albuminuria.
Type of the study: Comparative cross-sectional study
Adult patients with DM attending the internal medicine outpatient clinics and inpatient department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with diabetes mellitus who have no evidence of diabetic nephropathy will be defined by a normal urinary albumin-to-creatinine ratio (UACR) and preserved renal function.
Patients with diabetes mellitus and diabetic nephropathy will be defined by the presence of elevated UACR and/or impaired renal function as assessed by estimated glomerular filtration rate (eGFR). And within the diabetic nephropathy group, further subgroup analyses will be performed to assess differences in NHHR according to: 1. Type of diabetes (Type 1 vs. Type 2 diabetes mellitus) 2. Stages of chronic kidney disease (CKD) are classified based on KDIGO definitions of CKD based on estimated GFR and albuminuria.
Association between the non-high-density lipoprotein cholesterol-to-high-density lipoprotein cholesterol ratio (NHHR) and the presence of diabetic nephropathy.
Diabetic nephropathy defined as urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g and/or estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m², measured at enrollment. The non-HDL cholesterol to HDL cholesterol ratio (NHHR) will be calculated from fasting lipid profile obtained at the same visit.
Time frame: At baseline
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.